Frontier Biotech announced that Mr. RONGJIAN LU, the director and senior manager, held 21.7438 million shares of the company, accounting for 5.8049% of the total share capital; Mr. CHANGJIN WANG held 21.5595 million shares of the company, accounting for 5.6222% of the total share capital. Due to personal financial needs, the two plan to reduce their holdings through centralized bidding and/or bulk transactions from August 3, 2026 to November 2, 2026. Among them, Lu Rongjian plans to reduce his holdings by no more than 4.8 million shares, accounting for 1.2814% of the total share capital; Wang Changjin plans to reduce his holdings by no more than 4.8 million shares, accounting for 1.2814% of the total share capital. Together, the two reduced their holdings by no more than 9.6 million shares, accounting for 2.5628% of the total share capital.

Frontier Biotech announced that Mr. RONGJIAN LU, the director and senior manager, held 21.7438 million shares of the company, accounting for 5.8049% of the total share capital; Mr. CHANGJIN WANG held 21.5595 million shares of the company, accounting for 5.6222% of the total share capital. Due to personal financial needs, the two plan to reduce their holdings through centralized bidding and/or bulk transactions from August 3, 2026 to November 2, 2026. Among them, Lu Rongjian plans to reduce his holdings by no more than 4.8 million shares, accounting for 1.2814% of the total share capital; Wang Changjin plans to reduce his holdings by no more than 4.8 million shares, accounting for 1.2814% of the total share capital. Together, the two reduced their holdings by no more than 9.6 million shares, accounting for 2.5628% of the total share capital.